Angela Romanelli

This inventor holds 3 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignee: Debiopharm International, S.a.. Active years: 2022-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Angela Romanelli. Retrieved from https://idiyas.com/inventor/angela-romanelli

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 3 (Patent Applications = 3)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 4(Granted Patents)

Company Filing History:

3 out of 22

Debiopharm International, S.a.

patents

Years Active: 2022-2025

Loading Chart...

3 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12239732 - Anti-CD37 immunoconjugate and anti-CD20 antibody combinations (2025-03-04),

2. 11395796 - Anti-CD37 immunoconjugate and anti-CD20 antibody combinations (2022-07-26),

3. 11278629 - Methods for improving anti-CD37 immunoconjugate therapy (2022-03-22),

Title: Biography of Angela Romanelli

Introduction: Angela Romanelli is an accomplished inventor based in Lexington, MA (US). She has made significant contributions to the field of immunotherapy, particularly in the development of innovative treatments for cancer patients. With a total of three patents to her name, Angela has established herself as a leading figure in her area of expertise.

Latest Patents: Angela's latest patents include the development of anti-CD37 immunoconjugate and anti-CD20 antibody combinations. These patents focus on methods of administering immunoconjugates that bind to CD37, such as IMGN529, in combination with antibodies that bind to CD20. The methods are designed to provide effective treatment options for individuals in need, particularly cancer patients.

Career Highlights: Angela currently works at Debiopharm International, S.A., where she continues to innovate and advance her research. Her work has been instrumental in the development of new therapeutic strategies that aim to improve patient outcomes in oncology.

Collaborations: Throughout her career, Angela has collaborated with notable colleagues, including Rodrigo R Ruiz-Soto and Jose F Ponte. These partnerships have fostered a collaborative environment that enhances the research and development of groundbreaking treatments.

Conclusion: Angela Romanelli's contributions to the field of immunotherapy and her dedication to improving cancer treatment options make her a remarkable inventor. Her innovative patents and collaborative efforts continue to impact the

Profile summary based on public USPTO records.